OR WAIT null SECS
© 2022 MJH Life Sciences and Applied Clinical Trials Online. All rights reserved.
© 2022 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Applied Clinical Trials
September 01, 2018
Peter O’Donnell gauges the impact of FDA guidance on igniting the adaptive pathways debate in Europe.
From the Editor
A look at current strategies from the industry that address the limitations in clinical trials.
The emergence of CTiD offers the potential to remove future clinical failures much earlier in the process-and pave way for gains in R&D productivity.
Insights into the implementation of IDMP in the EU.
Click the title above to open the Applied Clinical Trials September 2018 issue in an interactive PDF format.
A Closing Thought
To support complex in-home clinical research and investigative sites, well-designed trials must produce the same high-quality data as traditional sites.
Jill Wechsler details new FDA policies to streamline drug development, including the design of “seamless” trials.
Industry experts look at how the specific needs of patients come into play when conducting gene-based screenings.
One nonprofit’s efforts to raise the relevance of the clinical research enterprise.
Alzheimer's Prevention Initiative's discusses a genetic counseling and disclosure model for its Generation Program.
How the use of M&S in cancer trials from the outset can help address those critical “what if?” scenarios and accelerate oncology drug development.
The region is significantly underrepresented in clinical development activity targeting childhood cancer.
Insights on the challenges, activity, and motives in merging bridging research and clinical care.
Site models that meet patient needs at the site level.
The role of the cloud in realizing the practical benefits of mHealth in clinical trials.
Partnership focuses on integrating research into the care continuum.
Case study highlights a new patient-centric enrollment model that uses a data-driven approach to identify qualified patients first.
Clinical Trial Insights
Reexamining traditional cycle-time reduction strategies is critical for sponsors, CROs, and sites.